Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

被引：328

作者：

Knight, Steven D. ^{[1
]}

Adams, Nicholas D. ^{[1
]}

Burgess, JoeIle L. ^{[1
]}

Chaudhari, Amita M. ^{[1
]}

Darcy, Michael G. ^{[1
]}

Donatelli, Carla A. ^{[1
]}

Luengo, Juan I. ^{[1
]}

Newlander, Ken A. ^{[1
]}

Parrish, Cynthia A. ^{[1
]}

Ridgers, Lance H. ^{[1
]}

Sarpong, Martha A. ^{[1
]}

Schmidt, Stanley J. ^{[1
]}

Van Aller, Glenn S. ^{[1
]}

Carson, Jeffrey D. ^{[1
]}

Diamond, Melody A. ^{[1
]}

Elkins, Patricia A. ^{[1
]}

Gardiner, Christine M. ^{[1
]}

Garver, Eric ^{[1
]}

Gilbert, Seth A. ^{[1
]}

Gontarek, Richard R. ^{[1
]}

Jackson, Jeffrey R. ^{[1
]}

Kershner, Kevin L. ^{[1
]}

Luo, Lusong ^{[1
]}

Raha, Kaushik ^{[1
]}

Sherk, Christian S. ^{[1
]}

Sung, Chiu-Mei ^{[1
]}

Sutton, David ^{[1
]}

Tummino, Peter J. ^{[1
]}

Wegrzyn, Ronald J. ^{[1
]}

Auger, Kurt R. ^{[1
]}

Dhanak, Dashyant ^{[1
]}

机构：

[1] GlaxoSmithKline Inc, Collegeville, PA 19426 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2010年 / 1卷 / 01期

关键词：

GSK2126458; phosphoinositide 3-kinase alpha; mammalian target of rapamycin; PI3K/AKT pathway; CANCER-SPECIFIC MUTATIONS; PHOSPHATIDYLINOSITOL; 3-KINASES; PIK3CA; PHOSPHORYLATION; IDENTIFICATION; P110-ALPHA; PATHWAY; CELL;

D O I：

10.1021/ml900028r

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Phosphomositide 3-kinase alpha (PI3K alpha) is a critical regulator of cell growth and transformation, and its signaling pathway is the most commonly mutated pathway in human cancers The mammalian target of rapamycin (mTOR), a class IV PI3K protein kinase, is also a central regulator of cell growth, and mTOR inhibitors are believed to augment the antiproliferative efficacy of PI3K/AKT pathway inhibition 2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide (GSK2126458, 1) has been identified as a highly potent, orally bioavailable inhibitor of PI3K alpha and mTOR with in vivo activity in both pharrnacodynamic and tumor growth efficacy models Compound 1 is currently being evaluated in human clinical trials for the treatment of cancer.

引用

页码：39 / 43

页数：5

共 50 条

[41] Identification of highly potent and selective PI3Kδ inhibitors
Marcoux, David
Quin, Lan-Ying
Ruan, Zheming
Shi, Qing
Ruan, Qian
Weigelt, Carolyn
Qiu, Hongchen
Schieven, Gary
Hynes, John
Bhide, Rajeev
Poss, Michael
Tino, Joseph
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (13) : 2849 - 2853
[42] Discovery of INCB098377: a potent inhibitor of phosphoinositide 3-kinase gamma (PI3Kγ)
Arias, Diana A.
Douglass, Stephen
Truong, Lisa
Wang, Qian
Wang, Kathy H.
Yang, Gengjie
Hansbury, Michael
O'Connor, Sybil
Bowman, Kevin
Collins, Robert
Stubbs, Matthew
Hall, Leslie
Stevens, Christina
Maddage, Christopher
Douty, Brent
Covington, Maryanne
Leffet, Lynn
Yue, Eddy
Combs, Andrew
Kim, Sunkyu
Shin, Niu
Koblish, Holly
Hess, Rodrigo
CANCER RESEARCH, 2023, 83 (07)
[43] Discovery of a Potent and Isoform-Selective Targeted Covalent Inhibitor of the Lipid Kinase PI3Kα
Nacht, Mariana
Qiao, Lixin
Sheets, Michael P.
St. Martin, Thia
Labenski, Matthew
Mazdiyasni, Hormoz
Karp, Russell
Zhu, Zhendong
Chaturvedi, Prasoon
Bhavsar, Deepa
Niu, Deqiang
Westlin, William
Petter, Russell C.
Medikonda, Aravind Prasad
Singh, Juswinder
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (03) : 712 - 721
[44] Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design
Cheng, Hengmiao
Bagrodia, Shubha
Bailey, Simon
Edwards, Martin
Hoffman, Jacqui
Hu, Qiyue
Kania, Robert
Knighton, Daniel R.
Marx, Matthew A.
Ninkovic, Sacha
Sun, Shaoxian
Zhang, Eric
MEDCHEMCOMM, 2010, 1 (02) : 139 - 144
[45] Neolymphostin A Is a Covalent Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitor That Employs an Unusual Electrophilic Vinylogous Ester
Castro-Falcon, Gabriel
Seiler, Grant S.
Demir, Ozlem
Rathinaswamy, Manoj K.
Hamelin, David
Hoffmann, Reece M.
Makowski, Stefanie L.
Letzel, Anne-Catrin
Field, Seth J.
Burke, John E.
Amaro, Rommie E.
Hughes, Chambers C.
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (23) : 10463 - 10472
[46] Discovery of fluoroquinolone derivatives as potent, selective inhibitors of PI3Kγ
Sha, Shao
Han, Hong-Wei
Gao, Fei
Liu, Tian-Bao
Li, Zhen
Xu, Chi
Zhong, Wei-Qing
Zhu, Hai-Liang
MEDCHEMCOMM, 2015, 6 (11) : 2029 - 2035
[47] Discovery of Potent and Selective Inhibitors of the Mammalian Target of Rapamycin (mTOR) Kinase
Nowak, Pawel
Cole, Derek C.
Brooijmans, Natasja
Bursavich, Matthew G.
Curran, Kevin J.
Ellingboe, John W.
Gibbons, James J.
Hollander, Irwin
Hu, YongBo
Kaplan, Joshua
Malwitz, David J.
Toral-Barza, Lourdes
Verheijen, Jeroen C.
Zask, Arie
Zhang, Wei-Guo
Yu, Ker
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (22) : 7081 - 7089
[48] Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer
Elfiky, Aymen A.
Aziz, Saadia A.
Conrad, Patricia J.
Siddiqui, Summar
Hackl, Wolfgang
Maira, Michel
Robert, Camp L.
Kluger, Harriet M.
JOURNAL OF TRANSLATIONAL MEDICINE, 2011, 9
[49] Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer
Aymen A Elfiky
Saadia A Aziz
Patricia J Conrad
Summar Siddiqui
Wolfgang Hackl
Michel Maira
Camp L Robert
Harriet M Kluger
Journal of Translational Medicine, 9
[50] Tivantinib Hampers the Proliferation of Glioblastoma Cells via PI3K/Akt/Mammalian Target of Rapamycin (mTOR) Signaling
Wu, Yukun
Li, Zhizhang
Zhang, Lijuan
Liu, Guiyang
MEDICAL SCIENCE MONITOR, 2019, 25 : 7383 - 7390

← 1 2 3 4 5 →